Incyte Corporation

Equities

INCY

US45337C1027

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-06-21 pm EDT 5-day change 1st Jan Change
63.22 USD +1.38% Intraday chart for Incyte Corporation +1.79% +0.68%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Incyte Insider Sold Shares Worth $1,149,840, According to a Recent SEC Filing MT
Incyte Reports Tender Offer Results MT
Tranche Update on Incyte Corporation's Equity Buyback Plan announced on May 13, 2024. CI
Incyte Reports Preliminary Tender Offer Results MT
Transcript : Incyte Corporation Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 08:00 AM
Incyte Corporation's Equity Buyback announced on May 13, 2024, has closed with 27,866,666 shares, representing 12.41% for $1,672 million. CI
Deutsche Bank Initiates Incyte to Hold Rating With $55 Price Target MT
Incyte Acquires 2 Office Buildings in Delaware MT
Transcript : Incyte Corporation Presents at Bank of America Health Care Conference 2024, May-15-2024 08:00 AM
Equities Close Mixed as Markets Weigh Consumer Inflation Survey MT
Equities Close Mixed as Markets Parse Consumer Inflation Survey MT
Equities Mixed Intraday as Markets Analyze Consumer Inflation Survey MT
Sector Update: Health Care Stocks Mixed in Afternoon Trading MT
Increasing Short-Term Inflation Expectations Weigh on US Equity Indexes Ahead of Consumer, Producer Prices MT
US Equity Indexes Trade Mixed as Short-Term Inflation Expectations Increase MT
Incyte Corporation announces an Equity Buyback for $1,672 million worth of its shares. CI
Sector Update: Health Care Stocks Decline Pre-Bell Monday MT
Incyte Launches $1.67 Billion Share Repurchase 'Dutch Auction' Tender Offer; to Buy Back $328 Million of Baker Entities' Shares MT
Incyte Corporation authorizes a Buyback Plan. CI
Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates MT
TD Cowen Adjusts Price Target on Incyte to $80 From $88 MT
RBC Capital Adjusts Price Target on Incyte to $60 From $65 MT
Piper Sandler Adjusts Price Target on Incyte to $80 From $85 MT
Goldman Sachs Adjusts Price Target on Incyte to $60 From $63 MT
Leerink Partners Adjusts Price Target on Incyte to $80 From $83, Keeps Outperform Rating MT
Chart Incyte Corporation
More charts
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (85.6%); - royalties (14.2%); - income from research and cooperation agreements (0.2%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
63.22 USD
Average target price
72.8 USD
Spread / Average Target
+15.15%
Consensus
  1. Stock Market
  2. Equities
  3. INCY Stock
  4. News Incyte Corporation
  5. Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates